Weight Loss with GLP-1
Experience proven, sustainable weight loss with medically-supervised GLP-1 therapy. Achieve your health goals with the support of our expert team.
What Are GLP-1 Medications?
GLP-1 (Glucagon-Like Peptide-1) medications are a class of prescription drugs that help with weight loss by mimicking a natural hormone in your body. These medications have been shown to produce significant, sustainable weight loss when combined with lifestyle modifications.
How GLP-1 Medications Work
Mimics Natural Hormones
GLP-1 medications work by mimicking the natural hormone GLP-1 that your body produces after eating, helping regulate appetite and blood sugar.
Reduces Appetite
By signaling to your brain that you're full, GLP-1 medications help reduce hunger and decrease calorie intake naturally.
Slows Digestion
These medications slow down how quickly food leaves your stomach, helping you feel satisfied longer after meals.
Improves Insulin Response
GLP-1 helps your pancreas release the right amount of insulin when blood sugar levels are high, improving overall metabolic health.
Benefits of GLP-1 Therapy
- Significant weight loss of 15-20% of body weight
- Reduced appetite and cravings
- Improved blood sugar control
- Lower cardiovascular risk factors
- Enhanced metabolic health
- Sustainable long-term results
* Individual results may vary. Clinical study averages are based on participants who followed the complete treatment protocol including dietary and lifestyle modifications. Your results may differ based on adherence, genetics, and other individual factors.
Available Therapies
GLP-1 medications including Semaglutide and Tirzepatide, may address your needs and health goals.
Semaglutide
A proven GLP-1 medication that has shown remarkable results in clinical studies, with an average weight loss of 15% of body weight.
How It Works
Semaglutide works by mimicking the natural GLP-1 hormone, reducing appetite, slowing digestion, and improving insulin response for sustainable weight loss and metabolic health improvements.
Protocol
- •Weekly subcutaneous injection
- •Start: 0.25mg once weekly × 4 weeks
- •Dosage increase: Increase by 0.25mg monthly, up to 2.5mg once weekly
- •Injection sites: Thigh, abdomen, or upper arm; rotate weekly
- •Doses may vary within 0.1-0.5mg within each dose based on doctor's recommendation
- •Protocol may be adjusted based on medical provider expertise
Key Benefits
- 12-15% average weight loss in STEP clinical trials*
- 20% cardiovascular risk reduction (SELECT trial)**
- HbA1c reduction of 1.0-1.8% in diabetes studies***
- Reduced fasting and post-prandial glucose
- Low hypoglycemia risk when used as monotherapy
- FDA-approved for chronic weight management with extensive clinical research
* Prescription required. Results based on clinical studies. Individual outcomes may vary.
Contraindications
Do Not Use:
- ✕Eating disorders (current or past bulimia, current or past anorexia nervosa)
- ✕Bulimia diagnosed <12 months ago
- ✕Pregnant or planning pregnancy
- ✕Breastfeeding
- ✕Recreational drug use (cocaine, methamphetamine)
Use With Caution:
- ⚠History of pancreatitis
- ⚠Thyroid disease or family history of medullary thyroid carcinoma
- ⚠Severe gastrointestinal disease
- ⚠Diabetic retinopathy
Common Side Effects:
- •Nausea (typically decreases over time)
- •Diarrhea or constipation
- •Fatigue
- •Injection site reactions
Clinical Evidence
- •STEP 1-4 trials demonstrated 12-15% mean body weight reduction over 68 weeks
- •SELECT cardiovascular outcomes trial showed 20% reduction in major adverse cardiovascular events
- •FDA approval based on Phase 3 trials with over 4,500 participants
Results from controlled clinical trials; individual outcomes may vary
Tirzepatide
A dual GIP/GLP-1 receptor agonist that may provide even greater weight loss, with studies showing up to 22% reduction in body weight.
How It Works
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. This unique dual action provides enhanced appetite control, improved insulin sensitivity, and superior weight loss outcomes compared to single-receptor GLP-1 medications.
Protocol
- •Weekly subcutaneous injection
- •Month 1: 2.0-2.5mg once weekly
- •Month 2: 4.0-5.0mg once weekly
- •Month 3: 7.0-7.5mg once weekly
- •Month 4: 9.0-10.0mg once weekly
- •Month 5: 12.0-12.5mg once weekly
- •Month 6: 14.0-15.0mg once weekly
- •Injection sites: Thigh, abdomen, or upper arm; rotate weekly
- •Protocol may be adjusted based on medical provider expertise
Key Benefits
- 15-22% average weight loss in SURMOUNT trials*
- Robust HbA1c reduction - up to 2.4% decrease in SURPASS studies**
- Dual GIP/GLP-1 advanced, synergistic mechanism
- Meaningful HbA1c reductions with low hypoglycemia risk
- Superior weight loss compared to single-receptor GLP-1 medications in head-to-head trials***
- FDA-approved for chronic weight management (Zepbound) and type 2 diabetes (Mounjaro)
* Prescription required. Results based on clinical studies. Individual outcomes may vary.
Contraindications
Do Not Use:
- ✕Eating disorders (current or past bulimia, current or past anorexia nervosa)
- ✕Pregnant or planning pregnancy
- ✕Breastfeeding
- ✕Recreational drug use (cocaine, methamphetamine)
- ✕Certain lab abnormalities or medications (consult provider)
Use With Caution:
- ⚠History of pancreatitis
- ⚠Thyroid disease or family history of medullary thyroid carcinoma
- ⚠Severe gastrointestinal disease
- ⚠Diabetic retinopathy
Common Side Effects:
- •Nausea (typically decreases over time)
- •Diarrhea or constipation
- •Fatigue
- •Injection site reactions
- •Decreased appetite
Clinical Evidence
- •SURMOUNT-1 trial: 22.5% mean weight reduction at 72 weeks with 15mg dose
- •SURPASS clinical program demonstrated superior glycemic control vs. semaglutide
- •FDA approval based on Phase 3 trials with over 6,000 participants across multiple studies
Results from controlled clinical trials; individual outcomes may vary significantly
Sermorelin
Growth hormone secretagogue peptide therapy
How It Works
Sermorelin stimulates the pituitary gland to naturally produce and release growth hormone. Unlike direct HGH therapy, sermorelin works with your body's natural processes to optimize hormone levels safely and effectively.
Protocol
- •Subcutaneous injection (5 days per week)
- •Females: Start at 0.1mg subcutaneously, five days per week
- •Males: Start at 0.2mg subcutaneously, five days per week
- •Injection sites: Rotate between abdomen, thigh, or upper arm
- •Inject before bedtime to mimic natural GH release
- •2 days off per week for optimal results
Key Benefits
- Natural stimulation - works with your body's systems
- Addresses the 14% annual HGH decline after age 30†
- May support increase in lean muscle mass in clinical studies
- Body composition improvements when combined with diet and exercise
- May enhance sleep quality and recovery†
- May improve skin elasticity and texture†
- May boost energy and vitality
- May support immune system function
* Prescription required. Results based on clinical studies. Individual outcomes may vary.
Contraindications
Do Not Use:
- ✕Known allergy or hypersensitivity to Sermorelin or components
- ✕Active cancer (especially GH-sensitive tumors like breast, prostate, pituitary)
- ✕Pituitary tumors or history of pituitary disease
Use With Caution:
- ⚠Diabetes or insulin resistance (monitor blood glucose)
- ⚠Pregnancy and breastfeeding (not studied in these populations)
- ⚠Children or adolescents (requires bone age monitoring)
- ⚠Thyroid dysfunction (may unmask hypothyroidism)
- ⚠Sleep apnea (may worsen fluid retention)
Common Side Effects:
- •Injection site reactions (redness, swelling)
- •Flushing at injection site
- •Headache (usually mild and transient)
- •Dizziness (rare)
- •Nausea (uncommon)
Clinical Evidence
- •Growth hormone secretagogue research demonstrates pituitary stimulation response
- •Studies show physiologic GH release patterns similar to natural secretion
- •Used in medical practice for growth hormone deficiency assessment and treatment
† Clinical evidence limited; more research needed. Individual responses vary significantly
Study References & Disclaimers
* STEP clinical trials: Phase 3 randomized controlled trials evaluating semaglutide for chronic weight management (n=1,961 in STEP 1). Participants received 2.4mg weekly subcutaneous injections with lifestyle interventions.
** SELECT cardiovascular outcomes trial: Major cardiovascular events in participants with pre-existing cardiovascular disease and overweight/obesity without diabetes.
*** SURPASS trials: Phase 3 studies comparing tirzepatide to placebo and active comparators in patients with type 2 diabetes. SURMOUNT trials evaluated tirzepatide for chronic weight management.
† Growth hormone decline: Based on published research on age-related changes in GH secretion. Individual baseline levels vary.
Important: All statistics and outcomes referenced are from controlled clinical trials and may not reflect real-world results. Individual patient outcomes will vary based on numerous factors including adherence, baseline health status, concurrent medications, lifestyle factors, and individual physiology. The prescribing provider will discuss evidence specific to your situation during consultation.
What to Expect
Initial Consultation
Your journey begins with a comprehensive consultation where we review your medical history, weight loss goals, and determine if GLP-1 therapy is right for you.
Personalized Treatment Plan
We create a customized treatment plan that includes your medication dosage, nutritional guidance, and lifestyle recommendations to maximize your success.
Ongoing Support
Regular check-ins with our team ensure you're progressing safely and effectively. We adjust your treatment as needed and provide continuous support throughout your weight loss journey.
Ready to Start Your Weight Loss Journey?
Schedule a consultation today to learn more about GLP-1 therapy and how it can help you achieve your weight loss goals.